Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The spinout of Yamaguchi University and National Cancer Centre Japan has raised the cash from investors including Dai-ichi Life and Binex.

The Cigna and Kaiser Permanente-backed mental healthcare app developer took its total funding to $220m in a round valuing it at about $1bn.

Retinal disease drug developer Gyroscope Therapeutics has raised series C funding from investors including Fosun Pharma.

Cambridge Innovation Capital has returned for a series C round for University of Cambridge-linked Gyroscope Therapeutics, which also welcomed back Syncona.

The solid tumour therapy developer secured $21.9m from investors including Dai-ichi Life, Binex, Bigen and Shibuya Kogyo.

Helsinn and Johnson & Johnson returned to add $21m in extra funding to the $44m series B round the surgical marker developer closed in 2018.

The University of Utah spinout is looking to float on the Nasdaq Global Select Market and has filed with a $100m placeholder amount.

Evidation, co-founded by Stanford University and GE Ventures, has picked up series E funding at a $1bn valuation.

The gene therapy developer focused on cardiovascular and central nervous system diseases will merge with Chardan Healthcare Acquisition 2 Corp to list on NYSE.